This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Risk for typical travelers is extremely low. Ebola spreads through direct contact with bodily fluids of infected persons. Avoid contact with sick individuals and bush meat. Outbreaks are localized — monitor WHO/CDC alerts. Vaccines are available for healthcare workers in outbreak zones.
Severe viral hemorrhagic fever with case fatality rates of 25–90%. Transmitted through direct contact with infected body fluids. Outbreaks primarily in Central and West Africa. Vaccine (Ervebo) available since 2019.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Fatigue | 76% | Mild | Early |
| Fever | 87% | Moderate | Early |
| Chills | 40% | Mild | Early |
| Headache | 53% | Mild | Early |
| Loss of appetite | 65% | Mild | Early |
| Malaise | 70% | Mild | Early |
| Myalgia | 49% | Mild | Early |
| Sore throat | 44% | Mild | Early |
| Arthralgia | 39% | Mild | Early |
| Diarrhea | 66% | Moderate | Peak |
| Vomiting | 68% | Moderate | Peak |
| Abdominal pain | 44% | Mild | Peak |
| Conjunctivitis | 30% | Mild | Peak |
| Nausea | 55% | Mild | Peak |
| Rash | 25% | Mild | Peak |
| Tachycardia | 30% | Moderate | Peak |
| Bleeding gums | 12% | Moderate | Late |
| Bloody stool | 6% | Severe | Late |
| Hemorrhage | 18% | Critical | Late |
| Hiccups | 15% | Mild | Late |
| Hypotension | 15% | Severe | Late |
| Petechiae | 15% | Moderate | Late |
| Shock | 20% | Critical | Late |
| Confusion | 15% | Severe | Late |
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe and often fatal illness caused by viruses of the genus Ebolavirus within the family Filoviridae. Six species have been identified, of which four cause disease in humans: Zaire ebolavirus (the most lethal, with case fatality rates averaging 50%), Sudan ebolavirus (CFR 40–60%), Bundibugyo ebolavirus (CFR ~25%), and Taï Forest ebolavirus (one known human case).
The disease is characterized by abrupt onset of fever, severe weakness, and gastrointestinal symptoms, progressing in severe cases to hemorrhagic manifestations, multi-organ failure, and death. Fruit bats of the Pteropodidae family are considered the most likely natural reservoir, though direct evidence remains incomplete.
EVD first emerged in 1976 with simultaneous outbreaks in Sudan and the Democratic Republic of the Congo (near the Ebola River, from which the virus takes its name). Since then, over 30 outbreaks have been recorded, almost exclusively in Central and West Africa. The 2014–2016 West African epidemic was the largest and most devastating, with 28,616 cases and 11,310 deaths across Guinea, Liberia, and Sierra Leone, demonstrating the catastrophic potential of Ebola in settings with fragile health systems.
Ebola virus is transmitted to humans through direct contact with the blood, secretions, organs, or other body fluids of infected animals (fruit bats, chimpanzees, gorillas, monkeys, forest antelope, porcupines). Human-to-human transmission occurs through direct contact with blood or body fluids of an infected person, or through contact with surfaces and materials contaminated with these fluids. The virus can persist in immunologically privileged sites — semen may remain positive for up to 18 months after recovery.
The incubation period ranges from 2 to 21 days, with a mean of 8–10 days. Patients are not infectious during the incubation period; infectiousness begins with symptom onset and increases as the disease progresses, correlating with rising viral load in blood and body fluids. Healthcare workers are at particular risk if infection prevention and control measures are inadequate — nosocomial transmission was a major amplifier in the 2014–2016 epidemic.
The pathogenesis of EVD involves widespread viral replication in macrophages, dendritic cells, and endothelial cells, triggering a dysregulated immune response ("cytokine storm"), disseminated intravascular coagulation, and vascular permeability leading to shock. Understanding of Ebola has advanced significantly in recent years, with the development of an effective vaccine and monoclonal antibody treatments transforming the prognosis for early-treated patients.
Ebola virus disease is a medical emergency at presentation. Any person with fever and relevant epidemiological risk factors (travel to an area with active Ebola transmission within the previous 21 days, or contact with a confirmed or suspected case) should be evaluated under strict infection prevention and control protocols immediately.
Critical warning signs that indicate progression to severe disease include: persistent vomiting and diarrhea with signs of severe dehydration (sunken eyes, poor skin turgor, weak pulse, confusion), any hemorrhagic manifestation (bleeding from gums, nose, eyes, or gastrointestinal tract, blood in vomit or stool, unexplained bruising), and altered mental status or obtundation suggesting encephalopathy or shock.
Healthcare facilities in non-endemic countries must activate their viral hemorrhagic fever protocols at the earliest suspicion. Patients should be isolated immediately in a single room with en-suite bathroom. All staff must use appropriate personal protective equipment (PPE) including fluid-resistant coverall, double gloves, face shield, FFP3/N95 respirator, and waterproof apron. Delay in isolation and PPE use has been the primary driver of nosocomial Ebola transmission in every major outbreak.
Most common signs and symptoms
Ebola virus disease presents with an abrupt onset of non-specific symptoms that can initially mimic malaria, typhoid fever, or other tropical infections. The illness typically progresses through three phases. The early phase (days 1–3) includes sudden high fever (>38.5°C), severe headache, myalgia, arthralgia, and profound fatigue. Sore throat and chest pain may also occur.
The gastrointestinal phase (days 3–10) is characterized by severe watery diarrhea, vomiting, and abdominal pain. Patients may lose up to 5–10 liters of fluid daily, leading to rapid dehydration and electrolyte derangements that, if untreated, are the primary cause of death. A maculopapular rash may appear on the trunk around day 5–7, which can be difficult to identify on dark skin.
Hemorrhagic manifestations occur in approximately 50% of cases, typically after day 5–7, and include petechiae, ecchymoses, mucosal bleeding (gingival, conjunctival), hematemesis, melena, and oozing from venipuncture sites. However, massive hemorrhage is less common than previously believed — the predominant cause of death is hypovolemic shock from fluid losses. In fatal cases, death typically occurs between days 6 and 16. Survivors begin to improve around days 7–12, though recovery is gradual and may take weeks to months.
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Infectivity: Not infectious during incubation. Infectivity increases with disease progression. Body fluids of dead patients are highly infectious.
How this disease is identified
Early diagnosis of Ebola virus disease is challenging because initial symptoms are non-specific and overlap with many common tropical infections, particularly malaria, which must always be tested for concurrently. The index of suspicion must be based on epidemiological risk assessment: recent travel to or residence in an area with known Ebola transmission, and/or contact with confirmed or suspected cases.
The primary diagnostic method is real-time reverse transcription polymerase chain reaction (RT-PCR) on blood specimens. PCR can detect viral RNA from approximately day 3 of symptoms (when viremia becomes detectable) and remains positive throughout the acute illness. Rapid diagnostic tests (RDTs) based on antigen detection are available for field use and provide results within 15–25 minutes — the WHO has recommended the OraQuick Ebola Rapid Antigen Test for use at point of care in outbreak settings, though PCR confirmation is still required.
Blood specimens from suspected Ebola patients are classified as UN 2814 Category A dangerous goods and must be handled, packaged, and transported under strict biosafety protocols. Testing should be performed in biosafety level 4 (BSL-4) laboratories, though validated PCR assays in BSL-3 containment with BSL-4 practices are accepted. ELISA-based IgM and IgG antibody detection is useful for epidemiological surveillance and confirming convalescence but is unreliable for acute diagnosis. Post-mortem diagnosis can be made by immunohistochemistry on skin biopsies.
Available treatment methods
The treatment of Ebola has been transformed by the development of monoclonal antibody therapies. Inmazeb (atoltivimab + maftivimab + odesivimab), a triple monoclonal antibody cocktail targeting the Ebola virus glycoprotein, received FDA approval in October 2020 — the first approved treatment for Zaire ebolavirus. In the PALM clinical trial in the DRC, Inmazeb reduced mortality from approximately 49% (with standard supportive care) to 34% overall, and to 11% when administered early in the disease course (low viral load at presentation).
Aggressive supportive care remains the foundation of EVD management and is critical regardless of whether specific therapies are available. This includes intravenous fluid resuscitation to replace massive gastrointestinal losses (often requiring 3–10 liters/day), correction of electrolyte abnormalities (particularly potassium, sodium, and bicarbonate), antiemetics, analgesics, and empiric antibiotics for secondary bacterial infections. Monitoring and replacement of coagulation factors may be necessary in patients with hemorrhagic complications.
The experience from the 2014–2016 epidemic demonstrated that survival improved dramatically with access to modern intensive care. In specialized Ebola treatment units in Western countries, where patients received ICU-level support, survival rates exceeded 80% — compared to 40–50% in field settings. This underscores that much of Ebola mortality is attributable to dehydration and metabolic derangement rather than the virus itself, and that early, aggressive fluid management saves lives.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Vaccination represents the most significant advance in Ebola prevention. rVSV-ZEBOV (Ervebo), a live recombinant vesicular stomatitis virus-based vaccine expressing the Zaire ebolavirus glycoprotein, demonstrated 97.5% efficacy in a landmark ring vaccination trial during the 2014–2016 West African epidemic. It received WHO prequalification in 2019 and is licensed in multiple countries. A single dose provides rapid protection, with immunity developing within 10 days. A second vaccine, Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea), uses a two-dose heterologous prime-boost regimen and is licensed in the EU.
In outbreak settings, ring vaccination — vaccinating contacts of confirmed cases and contacts of those contacts — has proven highly effective at containing spread. This strategy was instrumental in controlling the 2018–2020 DRC outbreak (Clade IIb) and has become standard practice. Pre-exposure vaccination is recommended for healthcare workers in endemic areas, laboratory personnel working with Ebola, and outbreak response teams.
Non-pharmaceutical prevention measures remain essential. In endemic regions, avoiding contact with fruit bats and non-human primates, thoroughly cooking animal products, and safe burial practices for Ebola victims are critical. In healthcare settings, rigorous infection prevention and control — including appropriate PPE, environmental decontamination with 0.5% chlorine solution, and safe waste management — prevents nosocomial transmission. Community engagement and trust-building are equally important, as distrust of health authorities has undermined control efforts in multiple outbreaks.
Preparation is the best protection.
Ebola outbreaks occur sporadically and unpredictably in Central and West Africa, with the Democratic Republic of the Congo, Guinea, Uganda, and South Sudan being the most frequently affected countries. Between outbreaks, the risk to travelers is effectively zero. During active outbreaks, risk to general travelers remains very low, as transmission requires direct contact with body fluids of infected individuals.
Before traveling to countries in the equatorial African forest belt, check the WHO Disease Outbreak News and CDC travel notices for active Ebola alerts. If an outbreak is ongoing at your destination, assess whether your travel is essential. Healthcare workers, journalists, and humanitarian workers deploying to outbreak zones should ensure pre-exposure vaccination with rVSV-ZEBOV (Ervebo) at least 10 days before deployment and receive training in appropriate PPE donning and doffing procedures.
During travel in endemic regions, avoid contact with wild animals, particularly fruit bats and non-human primates. Do not handle or consume bushmeat. Avoid visiting healthcare facilities treating Ebola patients unless you are trained and equipped. If someone you have been in close contact with develops symptoms consistent with Ebola, self-monitor your temperature twice daily for 21 days and report any fever (≥38°C) immediately to local health authorities. Do not travel by public transport if symptomatic.
Statistics and geographic data
Since the first recognized outbreaks in 1976, Ebola has caused more than 30 discrete outbreaks, almost exclusively in equatorial Africa. The disease remained relatively obscure for nearly four decades, with most outbreaks involving fewer than 500 cases and being contained within weeks to months through quarantine and contact tracing.
The 2014–2016 West African epidemic shattered this pattern catastrophically. Originating in rural Guinea in December 2013 and spreading to Liberia and Sierra Leone, it became the largest Ebola outbreak in history: 28,616 reported cases and 11,310 deaths. The epidemic exposed critical weaknesses in the Global Health Security architecture, overwhelmed the health systems of three countries, and caused severe socioeconomic disruption. Contributing factors included weak health infrastructure, delayed international response, population mobility across porous borders, cultural practices around burial, and community resistance to control measures.
The 2018–2020 outbreak in eastern DRC (North Kivu and Ituri provinces) was the second-largest on record, with 3,481 cases and 2,299 deaths. It was complicated by armed conflict and community distrust but was ultimately controlled using ring vaccination with rVSV-ZEBOV and rapid response teams. Subsequent smaller outbreaks in DRC, Guinea, and Uganda have reinforced the pattern of recurring spillover events. Climate change, deforestation, and increasing human encroachment into bat habitats may increase the frequency of zoonotic spillover events in the future.
Who is most at risk
The primary risk factor for Ebola virus disease is direct contact with body fluids of an infected person or animal. Specific high-risk activities include caring for Ebola patients without appropriate PPE, participating in traditional burial practices that involve washing or touching the body of someone who has died from Ebola, and handling or consuming bushmeat (wild animal meat, particularly bats and primates) in endemic regions.
Healthcare workers face the highest occupational risk. During the 2014–2016 West African epidemic, healthcare workers were infected at rates 21–32 times higher than the general population, with over 880 healthcare worker infections and more than 500 deaths. Risk is highest during the initial unrecognized phase of an outbreak, when patients present with non-specific febrile illness and standard infection control precautions may not yet be in place.
Laboratory workers handling clinical specimens from suspected Ebola patients are at risk if biosafety protocols are breached. Family members and close contacts of infected individuals face significant risk during home-based care, which was common during the 2014–2016 epidemic when treatment centers were overwhelmed. Immunocompromised individuals do not appear to have increased susceptibility to infection but may experience more severe disease. Living in or traveling to remote forested areas where zoonotic spillover events are most likely to originate increases baseline exposure risk.
Potential complications
Acute complications of Ebola virus disease are primarily driven by massive fluid loss and immune dysregulation. Hypovolemic shock from severe diarrhea and vomiting is the leading cause of death, compounded by metabolic acidosis, electrolyte derangements (particularly hypokalemia and hyponatremia), and acute kidney injury. Disseminated intravascular coagulation (DIC) underlies the hemorrhagic manifestations and contributes to multi-organ failure.
Secondary bacterial sepsis is an underrecognized but significant complication, as the damaged gut mucosa allows translocation of enteric bacteria. Hepatic failure, pancreatitis, and adrenal insufficiency may occur as the virus targets these organs. Neurological complications including meningoencephalitis, seizures, and coma carry a poor prognosis. Pregnant women have extremely high mortality rates (approximately 90% in some series), with near-universal fetal loss.
Survivors of Ebola virus disease frequently experience a constellation of chronic sequelae collectively termed "post-Ebola syndrome." The most common manifestation is uveitis, which can occur weeks to months after recovery and may lead to vision loss if untreated. Joint pain (arthralgia), chronic fatigue, headache, abdominal pain, and neuropsychological symptoms (insomnia, memory impairment, depression) affect a significant proportion of survivors. The virus can persist in immunologically privileged sites — notably semen (up to 18 months), anterior chamber of the eye, cerebrospinal fluid, and breast milk — raising concerns about sexual transmission and rare relapse events.
Expected outcomes and recovery
Ebola virus disease (Zaire ebolavirus):
Average CFR: 50% (range 25–90% depending on outbreak and healthcare availability).
With supportive care (IV fluids, electrolyte management): CFR 30–40%.
With advanced care (ICU, renal replacement): CFR <20% in recent outbreaks.
Monoclonal antibody treatment (mAb114/Inmazeb, REGN-EB3): reduced CFR to 6–11% in PALM trial.
Prognostic markers: High viral load (>10⁸ copies/mL), elevated creatinine, AST >1,000, age >40, hemorrhagic manifestations predict poor outcome.
Recovery: Survivors may experience post-Ebola syndrome (joint pain, fatigue, headaches, vision/hearing problems) for months to years. Virus may persist in immunologically privileged sites (eye, testes, CNS).
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useGeographic distribution and active outbreaks
| Flag | Country | Risk level |
|---|---|---|
 | Democratic Republic of the Congo | High risk |
 | Guinea | High risk |
 | Sierra Leone | High risk |
 | Uganda | High risk |
 | Liberia | High risk |
 | Congo | High risk |
 | South Sudan | High risk |
 | Mali | Medium risk |
 | Central African Republic | Medium risk |
 | Cameroon | Medium risk |
Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.